Researchers in the United States, Canada & Europe are testing Colchicine on approximately 6,000 participants for a period of 30 days.
The trial is to find out whether short-term treatment with colchicine will reduce lung complications and the rate of death in COVID-19 patients.
Colchicine is thought to decrease the ‘cytokine storm’ or inflammation that causes complications and death, in patients with COVID-19.
Colchicine has also currently been approved by FDA for gout and familial mediterranean fever.
Reference
https://clinicaltrials.gov/ct2/show/NCT04322682
https://www.physiciansweekly.com/anti-inflammatory-drug-colchicine-on-deck-for-covid-19/amp/
https://www.webmd.com/lung/news/20200422/could-an-ancient-drug-help-fight-severe-covid-19